For Patients and Caregivers
  • For Patients and Caregivers
  • Important Safety Information
  • Prescribing Information

This site is intended for US healthcare professionals only

zolgensma onasemnogene abeparvovec-xioi solution for intravenous infusion
  • Steps to treatment
  • About ZOLGENSMA
  • Understand SMA
  • Patient support
  • Resources
  • Get Connected
  • Pretreatment
  • Patient support
  • Dosing and infusion
  • Post treatment

*Required Field

To get connected with your ZOLGENSMA representative:
Call the OneGene Program™ 1-855-441-GENE (4363) Monday-Friday (8 am to 8 pm ET)

Resources

  • Pretreatment
  • Patient support
  • Dosing and infusion
  • Post treatment

Indication

ZOLGENSMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Limitations of Use
The safety and effectiveness of repeat administration or the use in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated with ZOLGENSMA.

Important Safety Information

BOXED WARNING: Acute Serious Liver Injury

Acute serious liver injury and elevated aminotransferases can occur with ZOLGENSMA. Patients with pre-existing liver impairment may be at higher risk. Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer a systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion.

WARNINGS AND PRECAUTIONS

Thrombocytopenia
Transient decreases in platelet counts, some of which met the criteria for thrombocytopenia, were observed at different time points after ZOLGENSMA infusion. Monitor platelet counts before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards.

Elevated Troponin-I
Transient increases in cardiac troponin-I levels were observed following ZOLGENSMA infusion. Monitor troponin-I before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards.

ADVERSE REACTIONS

The most commonly observed adverse reactions (incidence ≥5%) in clinical studies were elevated aminotransferases and vomiting.

Please see accompanying Full Prescribing Information.

BACK TO TOP

This website may use cookies to improve the site and your experience. See how AveXis collects, uses, and shares your personal information in our Privacy Policy.

  • PRIVACY POLICY
  • TERMS OF USE
  • SITE MAP
  • CONTACT US
image description
image description

© 2020 AveXis, Inc. All rights reserved.

US-ZOL-20-0182 06/2020

This site is intended for US healthcare professionals only.

You are now leaving
ZOLGENSMA-HCP.com:

AveXis provides links to third-party sites as a convenience and is not responsible for the content of these sites

Would you like to continue?
Click "No" to keep browsing ZOLGENSMA-hcp.com

Yes